Using PIPAC to prevent peritoneal carcinomatosis in advanced gastric cancer
Preventive Use of Pressurized Intraperitoneal Aerosol Chemotherapy in Locally Advanced Gastric Cancer: A Non-Randomized Controlled Study
This study is testing if a special type of chemotherapy given before surgery can help people with advanced stomach cancer avoid serious complications and live longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Research Oncology and Transplantology Center, Kazakhstan Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Astana) |
| Trial ID | NCT06784765 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) as a preoperative treatment for patients with locally advanced gastric cancer. The aim is to reduce the incidence of peritoneal carcinomatosis, a common and serious complication following surgery. Patients will receive PIPAC before undergoing neoadjuvant chemotherapy, with the hypothesis that this approach will improve survival rates and decrease recurrence. The study will assess overall survival and progression-free survival as secondary objectives.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 with histologically confirmed locally advanced gastric adenocarcinoma and negative peritoneal cytology.
Not a fit: Patients with distant metastases or positive peritoneal cytology will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival outcomes for patients with locally advanced gastric cancer by reducing the risk of peritoneal carcinomatosis.
How similar studies have performed: While PIPAC is a newer technique, preliminary studies have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Adults aged 18-70 years with histologically confirmed locally advanced gastric adenocarcinoma (T3-4N0-3M0), ECOG performance status 0-2, and negative peritoneal cytology. Inclusion Criteria: 1. Signed informed consent 2. Aged 18-70 years 3. ECOG performance status 0-2 4. Histologically confirmed adenocarcinoma of the stomach (T3-4N0-3M0) 5. Negative peritoneal cytology from diagnostic laparoscopy 6. No prior chemotherapy or radiotherapy Exclusion Criteria: 1. Presence of distant metastases 2. Positive peritoneal cytology 3. Previous cancer treatment (chemotherapy, radiotherapy, or surgery) 4. Severe comorbid conditions contraindicating surgery or chemotherapy 5. Pregnancy or lactation 6. Known hypersensitivity to study drugs
Where this trial is running
Astana
- National Research Oncology Centre — Astana, Kazakhstan (Recruiting)
Study contacts
- Study coordinator: Altay Kerimkulov, MD
- Email: altay.kerimkulov@gmail.com
- Phone: +77014382825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.